SCHEMBL9924429

SCHEMBL9924429

O=C(/N=C(/NCc1cccc(F)c1)N[C@H]1CC[C@H](O)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.43
KDM1A O60341 1/20 0.39
SRC P12931 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
SIGMAR1 Q99720 3/20 0.37
BRD4 O60885 2/20 0.37
JAK2 O60674 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
ROCK2 O75116 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924239 0.91 MAPK14 (0.36) ADRA1A
SCHEMBL9924241 0.91 SSTR3 (0.40) KDM1AALDH1A1SIGMAR1ROCK2
SCHEMBL9924242 0.89 LMNA (0.40) ALDH1A1
SCHEMBL9924428 0.89 SMYD3 (0.46) SIGMAR1
SCHEMBL9923857 0.87 LMNA (0.40) NTRK1DRD2ADRA1DADRA1AADRA1B
SCHEMBL9924268 0.86 SSTR3 (0.46) ALDH1A1
SCHEMBL9924426 0.86 EPHX1 (0.44) ALDH1A1
SCHEMBL9924237 0.86 SIGMAR1 (0.39) NTRK1ALDH1A1SIGMAR1ROCK2
SCHEMBL9924269 0.85 SSTR3 (0.45) ALDH1A1SIGMAR1
SCHEMBL9924243 0.85 P2RX7 (0.39) ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed